The Scientist - Home

The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.

Novartis, which bought the biotech firm in 2018, announced that the company’s top scientists have left, and news reports say it’s because they were involved in using manipulated data to get the gene therapy Zolgensma approved.

The results of an early trial in 31 brain cancer patients finds immune activity boosted in the tumor, and possibly longer survival.

In Niger, fewer kids die when health workers administer azithromycin routinely, perhaps because of a shift in the composition of gut microbes.

The fish’s undiscerning palate might make more of the lake habitable to the species than once thought, according to a new study.

REGN-EB3 and mAb114 reduced mortality in a clinical trial carried out during the ongoing outbreak in Democratic Republic of Congo.

Scientists found they could sort mouse sperm prior to IVF by treating semen with a drug that selectively slows down X-bearing cells.

Enforcement of the Endangered Species Act will be altered, easing protections for the most critically threatened plants and animals.

Submit your new product by the end of the day Monday to have a chance at being selected for a coveted spot in The Scientist's 2019 competition.

The 12-year-long endeavor reveals Prometheoarchaeum as a tentacled cell, living in a symbiotic relationship with methane-producing microbes.

Studies point to the life-saving record of fecal transplants for patients infected with C. diff, despite a recent death. Doctors are now testing the procedure for other conditions.

Nearly two dozen higher education groups warn the government to be cautious when advising US research universities to keep an eye on students and faculty with ties to certain Chinese institutions.